Received Apr 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
not received shingrix second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (The patient received Shingrix first dose on 08 July 2022 (lot number: P7K5P exp 10 September 2023)). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: not received shingrix second dose). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 22-APR-2025 An adult male patient received Shingrix first dose on 08 July 2022. The patient was going to have a transplant soon. The patient was not considered immunocompromised right now. The Vaccine Administration Facility was the same as Primary Reporter. Till the time of reporting the patient did not receive second dose of Shingrix which led to incomplete course of vaccination. Consented to follow up.